Phase 3 Readout~month

Phase 3 Topline: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tiv

Indication
Mucopolysaccharidosis II

Other upcoming events for DNLI

Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tiv — DNLI Phase 3 Readout | BioSniper